CPD | DIABETES
*Supplied content
Original paper:
Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan Mohamed Hassanein, Akram Salim Echtay, Rachid Malek, Mahomed Omard, Shehla Sajid Shaikh, Magnus Ekelund, Kadriye Kaplan, Nor Azmi Kamaruddin. Diabetes Res Clin Pract 2017; https://doi.org/10.1016/j.diabres.2017.11.027
Approximately 1.6 billion people worldwide are Muslims. Ramadan is the ninth month of the Islamic calendar, and fasting (total abstinence from food or drink) from dawn to sunset during Ramadan month is required. Each period of fasting may last up to 20 hours. The daily Ramadan fast starts after the pre-dawn meal – suhur, which is normally a small meal, and is concluded with a meal at sunset (iftar), which often includes a large amount of high-carbohydrate foods. In addition, at the end of Ramadan, there is a 3-day festival – Eid ul-Fitr, during which, overindulgence in food consumption is common even among patients with diabetes. Fasting during Ramadan is associated with an increased risk of dehydration and hypoglycaemia. In particular, patients with diabetes are at high risk of postprandial hyperglycaemia, diabetic ketoacidosis and thrombosis. Patients with very high or high risk include those with type 2 diabetes mellitus (T2DM) treated with premixed insulin or multiple daily insulin injections, many of whom choose to fast during Ramadan irrespective of knowing their risk of diabetic complications.
A
IM: To compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) and biphasic insulin aspart 30 (BIAsp 30) before, during and after Ramadan in patients with type 2 diabetes mellitus (T2DM) who fasted during Ramadan. METHODS: In this multinational, randomised, treatto-target trial, patients with T2DM who intended to fast and were on basal, pre- or self-mixed insulin +- oral antidiabetic drugs (OADs) for ≥ 90 days were randomised (1:1) to IDegAsp twice daily (BID) or BIAsp 30 BID. Treatment period included preRamadan treatment initiation (with insulin titration for 8 - 20 weeks), Ramadan (4 weeks) and post-Ramadan (4 weeks). Insulin doses were reduced by 30 - 50 % for the pre-dawn meal (suhur) on the first day of Ramadan, and readjusted to the preRamadan levels at the end of Ramadan. ENDPOINTS: The efficacy endpoints were change in HbA1c and fructosamine levels from baseline to the end of Ramadan (12 - 24 weeks) and from baseline to the end of post Ramadan (16 - 28 weeks), HbA1c responders (< 7 %) and 8-point self-measured plasma glucose (SMPG) profile at the end of Ramadan and post Ramadan. Hypoglycaemia was analysed as overall (severe or plasma glucose < 3.1 mmol/L), nocturnal (00:01 - 05:59) or severe (requiring assistance of another person). RESULTS: Glycaemic control was maintained in both treatment arms over the whole treatment
36 MAY 2020 | MEDICAL CHRONICLE
This is a CPD-accredited article, to do the questionnaire and earn points go to www.medicalacademic.co.za
